+1-858-251-2010 info@nucleusbiologics.com
  • LinkedIn
  • Facebook
  • Twitter
  • LinkedIn
  • Facebook
  • Twitter
0 Items
Nucleus Biologics
  • Home
  • Products
    • Physiologix™ XF SR
    • Vitronectin XF™
    • CMRL Media
  • Formulation Services
  • Quality
  • NB-Lux
  • NB-AIR
  • Krakatoa™
  • Education
    • Education
    • Technical Documentation
  • Our Purpose
    • Serving Science
    • Curing Disease
    • Leadership Team
    • Board of Directors
  • FAQ
  • Contact
    • Contact Us
    • Careers
Select Page
Development of a Cell Therapy to Restore Vision aided by Vitronectin XF™

Development of a Cell Therapy to Restore Vision aided by Vitronectin XF™

by Brad N. Taylor, Ph.D. | Feb 8, 2022

Age-related macular degeneration (AMD) is the degeneration/dysregulation of cells of the retinal pigment epithelium (RPE) and is the most common cause of severe loss of central vision among people 50 and older, affecting approximately 200 million people worldwide [1]....
Defining the Undefined with Vitronectin XF™ – Part 3

Defining the Undefined with Vitronectin XF™ – Part 3

by Brad N. Taylor, Ph.D. | Jan 18, 2022

Getting Attached In the final part of this 3-part blog series, Defining the undefined with Vitronectin XF™, get attached to Vitronectin even more as we delve into the performance data. In our previous blogs, we discussed how mixed extracellular matrix (ECM) gels such...
Defining the Undefined with Vitronectin XF™ – Part 2

Defining the Undefined with Vitronectin XF™ – Part 2

by Brad N. Taylor, Ph.D. | Jan 11, 2022

Clearing the Regulatory Hurdles Defined single component ECM gels have distinct advantages for stem cell therapies, improving patient safety and accelerating regulatory approval. Last week, we looked at the evolution in cell culture for mesenchymal (MSC) and induced...
Defining the Undefined with Vitronectin XF™ – Part 1

Defining the Undefined with Vitronectin XF™ – Part 1

by Brad N. Taylor, Ph.D. | Jan 4, 2022

Bringing Standardization to Stem Cell Process Development. A recombinant cell attachment factor brings standardization to stem cell production. Over the last few decades, human embryonic stem cells (hESCs) and subsequently induced pluripotent stem cells (iPSCs) have...
Nucleus Biologics™ acquires Primorigen Biosciences, gains proprietary, high yield, recombinant protein platform

Nucleus Biologics™ acquires Primorigen Biosciences, gains proprietary, high yield, recombinant protein platform

by Dr. Alyssa Master | Aug 5, 2019

  Nucleus Biologics™ now has the leading xeno-free, recombinant, extracellular matrix   SAN DIEGO – August 6, 2019 – Nucleus Biologics™, a leader in precision cell culture, is pleased to announce the acquisition of Primorigen Biosciences, Inc. The addition...

Search

Tags

cell culture media Cell Therapy Concierge IPSCs Islet cells Krakatoa Media Manufacturing MSCs NB-AIR NB Lux Press Release Reproducibility Stem Cells T Cell Vitronectin webinar XF
  • NB-Lux
  • NB-AIR
  • Krakatoa™
  • Products
  • Education
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • LinkedIn
  • Facebook
  • Twitter
©2022 Nucleus Biologics, LLC. All Rights Reserved.